Drug interactions of meglitinide antidiabetics involving CYP enzymes and OATP1B1 transporter.
Article Details
- CitationCopy to clipboard
Pakkir Maideen NM, Manavalan G, Balasubramanian K
Drug interactions of meglitinide antidiabetics involving CYP enzymes and OATP1B1 transporter.
Ther Adv Endocrinol Metab. 2018 Apr 6;9(8):259-268. doi: 10.1177/2042018818767220. eCollection 2018.
- PubMed ID
- 30181852 [ View in PubMed]
- Abstract
Meglitinides such as repaglinide and nateglinide are useful to treat type 2 diabetes patients who follow a flexible lifestyle. They are short-acting insulin secretagogues and are associated with less risk of hypoglycemia, weight gain and chronic hyperinsulinemia compared with sulfonylureas. Meglitinides are the substrates of cytochrome P450 (CYP) enzymes and organic anion transporting polypeptide 1B1 (OATP1B1 transporter) and the coadministration of the drugs affecting them will result in pharmacokinetic drug interactions. This article focuses on the drug interactions of meglitinides involving CYP enzymes and OATP1B1 transporter. To prevent the risk of hypoglycemic episodes, prescribers and pharmacists must be aware of the adverse drug interactions of meglitinides.
DrugBank Data that Cites this Article
- Drug Enzymes
Drug Enzyme Kind Organism Pharmacological Action Actions Nateglinide Cytochrome P450 2C9 Protein Humans UnknownSubstrateDetails Nateglinide Cytochrome P450 3A4 Protein Humans UnknownSubstrateDetails